Drug intelligence / Profile preview

KLA478

Development stage: Phase 1
Lead developer: Hunan Kelun Pharmaceutical
Modality: Small Molecules

Overview

**KLA478** is an investigational small molecule drug developed by Hunan Kelun Pharmaceutical Co., Ltd. Currently in Phase 1 clinical development, it is being evaluated in a first-in-human study (NCT07240675) assessing the safety, tolerability, and pharmacokinetics of single doses in healthy volunteers. No specific mechanism of action, therapeutic indications, or further development details are publicly disclosed.[7][9][10]

Beyond the preview

Go deeper on KLA478.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KLA478.

Explore the full profile